Fusion peptide is superior to co-expressing subunits for arming oncolytic herpes virus with interleukin 12

[1]  T. Todo,et al.  A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma , 2022, Nature Communications.

[2]  T. Todo,et al.  Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial , 2022, Nature Medicine.

[3]  T. Todo,et al.  Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma , 2021, Molecular therapy oncolytics.

[4]  F. Roohvand,et al.  Oncolytic herpes simplex virus type-1 expressing IL-12 efficiently replicates and kills human colorectal cancer cells. , 2021, Microbial pathogenesis.

[5]  H. Fukuhara,et al.  Oncolytic herpes virus G47Δ injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis , 2021, Molecular therapy oncolytics.

[6]  T. Todo,et al.  Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation , 2021, Molecular therapy oncolytics.

[7]  T. Todo,et al.  Neoadjuvant Use of Oncolytic Herpes Virus G47Δ Enhances the Antitumor Efficacy of Radiofrequency Ablation , 2020, Molecular therapy oncolytics.

[8]  R. Martuza,et al.  Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma , 2020, Journal for immunotherapy of cancer.

[9]  T. Todo,et al.  Efficacy of a Third-Generation Oncolytic Herpes Virus G47Δ in Advanced Stage Models of Human Gastric Cancer , 2020, Molecular therapy oncolytics.

[10]  P. Wen,et al.  Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial , 2019, Science Translational Medicine.

[11]  P. Lollini,et al.  A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors , 2018, PLoS pathogens.

[12]  E. Avitabile,et al.  HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses , 2018, Viruses.

[13]  H. Wakimoto,et al.  Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models , 2018, Clinical Cancer Research.

[14]  R. Martuza,et al.  Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. , 2017, Cancer cell.

[15]  R. Martuza,et al.  Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade , 2017, Oncoscience.

[16]  H. Fukuhara,et al.  Oncolytic virus therapy: A new era of cancer treatment at dawn , 2016, Cancer science.

[17]  R. Coffin.  Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer. , 2016, Immunotherapy.

[18]  Junjie Li,et al.  An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer. , 2013, Oncology reports.

[19]  H. Wakimoto,et al.  Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. , 2013, Neoplasia.

[20]  H. Wakimoto,et al.  Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model , 2013, Proceedings of the National Academy of Sciences.

[21]  J. Markert,et al.  Preclinical Evaluation of a Genetically Engineered Herpes Simplex Virus Expressing Interleukin-12 , 2012, Journal of Virology.

[22]  R. Martuza,et al.  Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  H. Fukuhara,et al.  Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  H. Fukuhara,et al.  Dominant-Negative Fibroblast Growth Factor Receptor Expression Enhances Antitumoral Potency of Oncolytic Herpes Simplex Virus in Neural Tumors , 2006, Clinical Cancer Research.

[25]  R. Martuza,et al.  Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers , 2006, Cancer Gene Therapy.

[26]  H. Fukuhara,et al.  Triple Combination of Oncolytic Herpes Simplex Virus-1 Vectors Armed with Interleukin-12, Interleukin-18, or Soluble B7-1 Results in Enhanced Antitumor Efficacy , 2006, Clinical Cancer Research.

[27]  H. Fukuhara,et al.  Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. , 2005, Cancer research.

[28]  H. Fukuhara,et al.  Oncolytic Herpes Simplex Virus Vector G47Δ in Combination with Androgen Ablation for the Treatment of Human Prostate Adenocarcinoma , 2005, Clinical Cancer Research.

[29]  T. Olencki,et al.  Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  N. Fraser,et al.  HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  R. Coffin,et al.  ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties , 2003, Gene Therapy.

[32]  R. Martuza,et al.  Replication-selective virotherapy for cancer: Biological principles, risk management and future directions , 2001, Nature Medicine.

[33]  R. Martuza,et al.  Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Shah,et al.  Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. , 2001, Human gene therapy.

[35]  W. Somers,et al.  Charged residues dominate a unique interlocking topography in the heterodimeric cytokine interleukin‐12 , 2000, The EMBO journal.

[36]  J. Markert,et al.  Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. Martuza,et al.  Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. , 1999, Human gene therapy.

[38]  E. Venetsanakos,et al.  Interleukin-12 induces an effective antitumor response in malignant mesothelioma. , 1998, American journal of respiratory cell and molecular biology.

[39]  R. Martuza,et al.  In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. , 1998, Journal of immunology.

[40]  M. Atkins,et al.  Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  J Cohen,et al.  IL-12 Deaths: Explanation and a Puzzle , 1995, Science.

[42]  R. Martuza,et al.  Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas , 1995, Nature Medicine.

[43]  D. Andrews,et al.  A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes , 1994, Cell.

[44]  Susanne A. Fischer,et al.  The interleukin‐12 subunit p40 specifically inhibits effects of the interleukin‐12 heterodimer , 1993, European journal of immunology.

[45]  Giorgio,et al.  Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells , 1992, The Journal of experimental medicine.

[46]  P. Familletti,et al.  Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[47]  D M Coen,et al.  Experimental therapy of human glioma by means of a genetically engineered virus mutant , 1991, Science.

[48]  R. Hewick,et al.  Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. , 1991, Journal of immunology.

[49]  F. Podlaski,et al.  Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[50]  G. Trinchieri,et al.  Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes , 1989, Journal of Experimental Medicine.

[51]  C. López.  Genetics of natural resistance to herpesvirus infections in mice , 1975, Nature.

[52]  OUP accepted manuscript , 2021, Neuro-Oncology.

[53]  J. Markert,et al.  Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. , 2016, Human gene therapy. Clinical development.

[54]  J. Markert,et al.  Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. , 2016, Human gene therapy. Clinical development.

[55]  J. Markert,et al.  Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. , 2014, Human gene therapy. Clinical development.